SOURCE: Graybug Vision, Inc.

Graybug Vision, Inc.

April 25, 2016 08:00 ET

Ophthalmology Product Company Graybug Vision to Present Data at ARVO 2016

REDWOOD CITY, CA--(Marketwired - Apr 25, 2016) - Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that data from its preclinical research will be highlighted in presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting, taking place May 1 to 5 in Seattle, WA.

Graybug Vision has two products in preclinical development for the treatment of ocular diseases. Its lead product, GB-102, is a novel injectable depot formulation containing a compound blocking VEGF and PDGF receptors for twice a year treatment of wet AMD.

On May 2nd, Peter A. Campochiaro, MD, Director, Retinal Cell and Molecular Laboratory at Johns Hopkins University Wilmer Eye Institute, will present data from a murine study of GB-102 in a poster entitled "Sustained Suppression of Murine Choroidal Neovascularization by Intravitreous Injection of Sunitinib-encapsulated Polymer Microparticles."

On May 4th, Graybug Vision researchers Ming Yang, PhD, and Ward M. Peterson, PhD, will present data from an in vivo toxicology/PK study of GB-102 in a poster entitled "GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months."

Details of the poster presentations are as follows:

Title: Sustained Suppression of Murine Choroidal Neovascularization by Intravitreous Injection of Sunitinib-encapsulated Polymer Microparticles
Poster Number: 2147 - C0054
Session Title: AMD and CNV: Clinical and Translational
Date:
Monday, May 2, 2016
Time: 11:00 AM to 12:45 PM

Title: GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months
Poster Number: 5037 - B0243
Session Title: Anti-VEGF
Date:
Wednesday, May 4, 2016
Time: 11:00 AM to 12:45 PM

About Graybug Vision
Graybug Vision is developing novel products for the treatment of ocular diseases. Graybug Vision's technologies enable the delivery of compounds to the eye up to twice per year and were co-developed by Graybug Vision founder Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with Graybug Vision cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD. Graybug Vision's lead product, GB-102, is being developed for twice a year treatment of wet AMD patients. Graybug Vision's second product consists of compounds with intraocular pressure lowering and neuroprotection that may be administered to the subconjunctiva twice per year for the treatment of glaucoma. For more information, please visit www.graybug.com.

Contact Information

  • Graybug Vision, Inc. Corporate
    Jeffrey L. Cleland, PhD
    650-868-5853
    Email Contact
    or
    Graybug Vision, Inc. Media
    Debra Bannister
    530-676-7373
    Email Contact